Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1999 Oct 1;343(Pt 1):199–207.

Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

P O Falnes 1, R Welker 1, H G Kräusslich 1, S Olsnes 1
PMCID: PMC1220542  PMID: 10493930

Abstract

Diphtheria toxin enters the cytosol of mammalian cells where it inhibits cellular protein synthesis, leading to cell death. Recently we found that the addition of a signal for N-end-rule-mediated protein degradation to diphtheria toxin substantially reduced its intracellular stability and toxicity. These results prompted us to construct a toxin containing a degradation signal that is removable through the action of a viral protease. In principle, such a toxin would be preferentially stabilized, and thus activated, in cells expressing the viral protease in the cytosol, i.e. virus-infected cells, thereby providing a specific eradication of these cells. In the present work we describe the construction of toxins that contain a signal for N-end-rule-mediated degradation just upstream of a cleavage site for the protease from HIV type 1 (HIV-1 PR). We show that the toxins are cleaved by HIV-1 PR exclusively at the introduced sites, and thereby are converted from unstable to stable proteins. Furthermore, this cleavage substantially increased the ability of the toxins to inhibit cellular protein synthesis. However, the toxins were unable to selectively eradicate HIV-1-infected cells, apparently due to low cytosolic HIV-1 PR activity, since we could not detect cleavage of the toxins by HIV-1 PR in infected cells. Alternative strategies for the construction of toxins that can specifically be activated by viral proteases are discussed.

Full Text

The Full Text of this article is available as a PDF (308.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi A., Gendelman H. E., Koenig S., Folks T., Willey R., Rabson A., Martin M. A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986 Aug;59(2):284–291. doi: 10.1128/jvi.59.2.284-291.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adams L. D., Tomasselli A. G., Robbins P., Moss B., Heinrikson R. L. HIV-1 protease cleaves actin during acute infection of human T-lymphocytes. AIDS Res Hum Retroviruses. 1992 Feb;8(2):291–295. doi: 10.1089/aid.1992.8.291. [DOI] [PubMed] [Google Scholar]
  3. Arora N., Leppla S. H. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J Biol Chem. 1993 Feb 15;268(5):3334–3341. [PubMed] [Google Scholar]
  4. Billich A., Winkler G. Analysis of subsite preferences of HIV-1 proteinase using MA/CA junction peptides substituted at the P3-P1' positions. Arch Biochem Biophys. 1991 Oct;290(1):186–190. doi: 10.1016/0003-9861(91)90606-j. [DOI] [PubMed] [Google Scholar]
  5. Clavel F., Charneau P. Fusion from without directed by human immunodeficiency virus particles. J Virol. 1994 Feb;68(2):1179–1185. doi: 10.1128/jvi.68.2.1179-1185.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Duesbery N. S., Webb C. P., Leppla S. H., Gordon V. M., Klimpel K. R., Copeland T. D., Ahn N. G., Oskarsson M. K., Fukasawa K., Paull K. D. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 1998 May 1;280(5364):734–737. doi: 10.1126/science.280.5364.734. [DOI] [PubMed] [Google Scholar]
  7. Falnes P. O., Olsnes S. Cell-mediated reduction and incomplete membrane translocation of diphtheria toxin mutants with internal disulfides in the A fragment. J Biol Chem. 1995 Sep 1;270(35):20787–20793. doi: 10.1074/jbc.270.35.20787. [DOI] [PubMed] [Google Scholar]
  8. Falnes P. O., Olsnes S. Modulation of the intracellular stability and toxicity of diphtheria toxin through degradation by the N-end rule pathway. EMBO J. 1998 Jan 15;17(2):615–625. doi: 10.1093/emboj/17.2.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Falnes P. O., Wiedłocha A., Rapak A., Olsnes S. Farnesylation of CaaX-tagged diphtheria toxin A-fragment as a measure of transfer to the cytosol. Biochemistry. 1995 Sep 5;34(35):11152–11159. doi: 10.1021/bi00035a021. [DOI] [PubMed] [Google Scholar]
  10. Gonda D. K., Bachmair A., Wünning I., Tobias J. W., Lane W. S., Varshavsky A. Universality and structure of the N-end rule. J Biol Chem. 1989 Oct 5;264(28):16700–16712. [PubMed] [Google Scholar]
  11. Hancock J. F., Cadwallader K., Paterson H., Marshall C. J. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J. 1991 Dec;10(13):4033–4039. doi: 10.1002/j.1460-2075.1991.tb04979.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kaplan A. H., Swanstrom R. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4528–4532. doi: 10.1073/pnas.88.10.4528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kimpton J., Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol. 1992 Apr;66(4):2232–2239. doi: 10.1128/jvi.66.4.2232-2239.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Klimpel K. R., Molloy S. S., Thomas G., Leppla S. H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10277–10281. doi: 10.1073/pnas.89.21.10277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Konvalinka J., Litterst M. A., Welker R., Kottler H., Rippmann F., Heuser A. M., Kräusslich H. G. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity. J Virol. 1995 Nov;69(11):7180–7186. doi: 10.1128/jvi.69.11.7180-7186.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kräusslich H. G., Wimmer E. Viral proteinases. Annu Rev Biochem. 1988;57:701–754. doi: 10.1146/annurev.bi.57.070188.003413. [DOI] [PubMed] [Google Scholar]
  17. Leppla S. H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A. 1982 May;79(10):3162–3166. doi: 10.1073/pnas.79.10.3162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. London E. Diphtheria toxin: membrane interaction and membrane translocation. Biochim Biophys Acta. 1992 Mar 26;1113(1):25–51. doi: 10.1016/0304-4157(92)90033-7. [DOI] [PubMed] [Google Scholar]
  19. Milne J. C., Blanke S. R., Hanna P. C., Collier R. J. Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol Microbiol. 1995 Feb;15(4):661–666. doi: 10.1111/j.1365-2958.1995.tb02375.x. [DOI] [PubMed] [Google Scholar]
  20. Pandori M. W., Fitch N. J., Craig H. M., Richman D. D., Spina C. A., Guatelli J. C. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol. 1996 Jul;70(7):4283–4290. doi: 10.1128/jvi.70.7.4283-4290.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Polesskaia A. N., Garred O., Olsnes S., Kozlov Iu V. Samoingibirovanie N-glikozidaznoi aktivnosti toksina shigelly. Mol Biol (Mosk) 1997 May-Jun;31(3):528–535. [PubMed] [Google Scholar]
  22. Rivière Y., Blank V., Kourilsky P., Israël A. Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection. Nature. 1991 Apr 18;350(6319):625–626. doi: 10.1038/350625a0. [DOI] [PubMed] [Google Scholar]
  23. Roberts N. A., Martin J. A., Kinchington D., Broadhurst A. V., Craig J. C., Duncan I. B., Galpin S. A., Handa B. K., Kay J., Kröhn A. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990 Apr 20;248(4953):358–361. doi: 10.1126/science.2183354. [DOI] [PubMed] [Google Scholar]
  24. Tomasselli A. G., Heinrikson R. L. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. Methods Enzymol. 1994;241:279–301. doi: 10.1016/0076-6879(94)41069-0. [DOI] [PubMed] [Google Scholar]
  25. Tomasselli A. G., Hui J. O., Sawyer T. K., Staples D. J., Bannow C., Reardon I. M., Howe W. J., DeCamp D. L., Craik C. S., Heinrikson R. L. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem. 1990 Aug 25;265(24):14675–14683. [PubMed] [Google Scholar]
  26. Tözsér J., Bláha I., Copeland T. D., Wondrak E. M., Oroszlan S. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 1991 Apr 9;281(1-2):77–80. doi: 10.1016/0014-5793(91)80362-7. [DOI] [PubMed] [Google Scholar]
  27. Van Oijen M. G., Preijers F. W. Rationale for the use of immunotoxins in the treatment of HIV-infected humans. J Drug Target. 1998;5(2):75–91. doi: 10.3109/10611869808995861. [DOI] [PubMed] [Google Scholar]
  28. Varshavsky A. The N-end rule. Cold Spring Harb Symp Quant Biol. 1995;60:461–478. doi: 10.1101/sqb.1995.060.01.051. [DOI] [PubMed] [Google Scholar]
  29. Vocero-Akbani A. M., Heyden N. V., Lissy N. A., Ratner L., Dowdy S. F. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med. 1999 Jan;5(1):29–33. doi: 10.1038/4710. [DOI] [PubMed] [Google Scholar]
  30. Welker R., Kottler H., Kalbitzer H. R., Kräusslich H. G. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology. 1996 May 1;219(1):228–236. doi: 10.1006/viro.1996.0240. [DOI] [PubMed] [Google Scholar]
  31. Wesche J., Elliott J. L., Falnes P. O., Olsnes S., Collier R. J. Characterization of membrane translocation by anthrax protective antigen. Biochemistry. 1998 Nov 10;37(45):15737–15746. doi: 10.1021/bi981436i. [DOI] [PubMed] [Google Scholar]
  32. Wlodawer A., Miller M., Jaskólski M., Sathyanarayana B. K., Baldwin E., Weber I. T., Selk L. M., Clawson L., Schneider J., Kent S. B. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 1989 Aug 11;245(4918):616–621. doi: 10.1126/science.2548279. [DOI] [PubMed] [Google Scholar]
  33. Yamaizumi M., Mekada E., Uchida T., Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978 Sep;15(1):245–250. doi: 10.1016/0092-8674(78)90099-5. [DOI] [PubMed] [Google Scholar]
  34. di Marzo Veronese F., Copeland T. D., DeVico A. L., Rahman R., Oroszlan S., Gallo R. C., Sarngadharan M. G. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science. 1986 Mar 14;231(4743):1289–1291. doi: 10.1126/science.2418504. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES